Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.22 USD | +1.83% | +37.04% | -66.83% |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 69.68 | 77.01 | 17.59 | 8.242 | 6.34 | - | - |
Enterprise Value (EV) 1 | 69.68 | 77.01 | 17.59 | 8.242 | 6.34 | 6.34 | 6.34 |
P/E ratio | -2.6 x | -6.53 x | -0.65 x | -0.79 x | -0.58 x | -0.56 x | -0.36 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | 0.32 x |
EV / Revenue | - | - | - | - | - | - | 0.32 x |
EV / EBITDA | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 528 | 786 | 800 | 1,232 | 2,856 | - | - |
Reference price 2 | 131.9 | 98.00 | 22.00 | 6.692 | 2.220 | 2.220 | 2.220 |
Announcement Date | 3/25/21 | 3/30/22 | 3/30/23 | 3/29/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 20 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | -6.437 | -11.57 | -20.26 | -11.46 | -11.3 | -14.04 | 7.696 |
Operating Margin | - | - | - | - | - | - | 38.48% |
Earnings before Tax (EBT) 1 | -15.41 | -11.96 | -27.42 | -11.12 | -10.96 | -13.74 | -14.61 |
Net income 1 | -14.41 | -11.43 | -27.42 | -11.12 | -12.56 | -14.08 | -14.61 |
Net margin | - | - | - | - | - | - | -73.04% |
EPS 2 | -50.80 | -15.00 | -34.00 | -8.480 | -3.820 | -3.945 | -6.200 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/25/21 | 3/30/22 | 3/30/23 | 3/29/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -3.111 | -3.369 | -3.229 | -5.172 | -6.057 | -5.8 | -4.106 | -2.714 | -2.168 | -2.469 | -2.55 | -2.65 | -2.9 | -3.2 | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -3.11 | -3.366 | -3.227 | -5.164 | -6.02 | -13.01 | -4.022 | -2.613 | -2.082 | -2.405 | -2.455 | -2.57 | -2.84 | -3.09 | - |
Net income | -2.987 | -3.184 | -3.227 | -5.164 | -6.02 | -13.01 | -4.022 | -2.613 | -2.082 | -2.405 | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -3.800 | -4.200 | -4.000 | -6.400 | -7.400 | -16.00 | -3.600 | -2.000 | -1.600 | -8.140 | -1.180 | -0.9000 | -0.9900 | -0.8400 | -0.5600 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/12/21 | 3/30/22 | 5/12/22 | 8/11/22 | 11/8/22 | 3/30/23 | 5/15/23 | 8/10/23 | 11/13/23 | 3/29/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | - | - | - | - | 1 |
Capex / Sales | - | - | - | - | - | - | 5% |
Announcement Date | 3/25/21 | 3/30/22 | 3/30/23 | 3/29/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.83% | 6.34M | |
+33.25% | 699B | |
+28.59% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+14.81% | 236B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- PCSA Stock
- Financials Processa Pharmaceuticals, Inc.